化疗联合DC-CIK治疗小细胞肺癌的临床研究  

Clinical efftcts of chemotherapy combined with DC-CIK in treatment of SCLC

作　　者：闵敏[1] 于学军[2] 陈利君[3] 江莉[1] 游雪梅[1] 钟国成[1] 

机构地区：[1]解放军452医院肿瘤科,成都610021 [2]解放军452医院感染科,成都610021 [3]解放军452医院医学影像科,成都610021

出　　处：《西南国防医药》2017年第6期560-563,共4页Medical Journal of National Defending Forces in Southwest China

摘　　要：目的研究化疗与过继免疫(树突状细胞-细胞因子诱导杀伤细胞,DC-CIK)在小细胞肺癌(SCLC)联合治疗中的协同机制和临床疗效。方法 60例SCLC患者随机分为两组:化疗组30例,接受全身化疗4~8周期;联合组30例,除接受相同疗程的化疗外,还接受自身DC-CIK免疫治疗4~8周期。观察联合组在第1次化疗前后的免疫指标变化,比较两组治疗后生活质量、实验室指标和临床疗效。结果联合组第1次化疗后,体内免疫抑制指标明显下降;治疗后3个月,联合组的生活质量和实验室指标均优于化疗组(P<0.05);治疗后6个月,联合组的临床疗效优于化疗组(P<0.05)。结论化疗能减弱联合组患者体内部分免疫抑制指标;化疗联合DC-CIK治疗能提高SCLC患者的临床疗效。Obective To study the synergy mechanism and effects of chemotherapy and adoptive immunity （dendritic cell- cytokine induced killer cells, DC-CIK） in the combined treatment of small cell lung cancer （SCLC）. MeAods A total of 60 SCLC patients were randomly divided into a chemotherapy group and a combination group（n=30, respectively）. The chemotherapy group was treated with systemic chemotherapy for 4-8 cycles, while the combination group was additionally treated with autologous DC-CIK immunotherapy for 4-8 cycles. The changes in the immune indexes in the combination group before and after the first chemotherapy were observed. The post-treatment life quality, laboratory indexes and effects between the two groups were compared. Results The in vivo immune suppression indexes after the first chemotherapy in the combination group decreased significantly; three months after the treatment, the life quality and laboratory indexes in the combination group were better that those in the chemotherapy group（P 〈 0.05）; six months after the treatment, the effects in the combination group were better that those in the chemotherapy group （P 〈 0.05）. Conclusion Chemotherapy can lower partial immune suppression indexes of patients in the combination group; chemotherapy combined with DC-CIK can improve the effects in the treatment of SCLC.

关 键 词：小细胞肺癌 免疫化疗 树突状细胞 细胞因子诱导杀伤细胞 疗效 

分 类 号：R734.2[医药卫生—肿瘤]